Skip to main content

Table 1 Clinical findings at baseline and 6-month follow up in patients with psoriatic arthritis

From: Ultrasound composite scores for the assessment of inflammatory and structural pathologies in Psoriatic Arthritis (PsASon-Score)

 

Baseline visit (n =83)

Follow up at 6 months (n =70)

P-value

Age at inclusion, years

51.8 (11.7)

n.a.

n.a.

Female, n (%)

22 (26.2)

n.a.

n.a.

Body mass index, kg/m2‡

27.2 (18.5 to 46.8)

n.a.

n.a.

Disease duration, years

7.5 (0 to 44.7)

n.a.

n.a.

Patients with a new diagnosis¥, n (%)

4 (4.8)

n.a.

n.a.

Axial involvement, n (%)

11 (13.3)

n.a.

n.a.

Smokers, n (%)

 

n.a.

n.a.

Current

21 (25.3)

Previous

32 (38.6)

PASDAS‡

5.9 (1.5)

5.2 (1.5)

<0.001

DAPSA‡

11.5 (0.1 to 70.2)

7.2 (0.1 to 73.5)

0.016

CPDAI‡

3.0 (0 to 9.0)

2.0 (0 to 11.0)

0.019

CRP, mg/L ‡

2.2 (0 to 49.5)

2.4 (0.2 to 35.0)

n.s.

ESR, mm/1st hour‡

9.5 (1 to 74)

10 (2 to 51)

n.s.

TJ, 68-joint count‡

4 (0 to 59)

1 (0 to 53)

0.012

SJ, 66-joint count‡

1 (0 to 15)

0 (0 to 17)

0.011

PGA, mm†

31.2 (22.7)

21.3 (23.5)

0.073

Ptpain, mm†

30.5 (24.5)

20.7 (21.0)

<0.001

EGA, mm†

22.0 (19.1)

11.5 (14.6)

0.009

HAQ†

0.7 (0.8)

0.6 (0.7)

<0.001

BASDAI‡

4.7 (0.9 to 5.5)

3.0 (0 to 6.0)

n.s.

ASQol‡

2.0 (0 to 11.0)

4.0 (0 to 8.0)

n.s.

Leeds enthesitis score‡

0 (0 to 4)

0 (0 to 2)

n.s.

Dactylitis score‡

0 (0 to 10)

0 (0 to 4)

n.s.

PASI‡

1.0 (0 to 23.2)

0.4 (0 to 36.3)

n.s.

DLQI‡

1.0 (0 to 20.0)

1.0 (0 to 18.0)

n.s.

DMARDs, n (%)

  

n.s.

MTX

33 (39.8)

30 (42.9)

LFN

11 (13.3)

12 (17.1)

MTX + LFN

3 (3.6)

3 (4.3)

SSZ

2 (2.4)

2 (2.9)

Anti-TNFα

31 (37.3)

30 (42.9)

Corticosteroids, n (%)

6 (7.2)

4 (5.7)

n.s.

NSAIDs, n (%)

  

n.s.

On demand

56 (67.5)

57 (81.4)

Regular intake

10 (12.0)

8 (11.4)

  1. Median (range); mean (standard deviation); P-values are not adjusted for multiple testing; ¥diagnosis was established at the day of baseline study visit. ASQol, ankylosing spondylitis quality of life; BASDAI, Bath ankylosing spondylitis disease activity index; CPDAI, composite psoriatic disease activity index; CRP, C-reactive protein (normal values 0 to 5 mg/L); DAPSA, disease activity index for psoriatic arthritis; DLQI, dermatology life quality index; DMARDs, disease-modifying anti-rheumatic drugs; EGA, evaluator’s global assessment of disease activity; ESR, erythrocyte sedimentation rate (normal values 1 to 10 mm/1st hour); HAQ, health assessment questionnaire; LFN, leflunomide; MTX, methotrexate; n, number; n.a., not applicable; n.s., not statistically significant; NSAIDs, non-steroidal anti-inflammatory drugs; PASDAS, psoriatic arthritis disease activity score; PASI, psoriasis area and severity index; PGA, patients’ global assessment of disease activity; Ptpain, patients’ pain assessment; SJ, swollen joint count; SSZ, sulfasalazine; TJ, tender joint count; TNF, tumour necrosis factor alpha. PGA, Ptpain and EGA were measured on visual analogue scales (range 0 to 100 mm) and are expressed in mm; BASDAI and ASQol values are shown for those 11 (13.3%) PsA patients with axial involvement.